Medical technology company Stryker has secured pre-market approval from the US Food and Drug Administration (FDA) for the use of its Surpass Streamline Flow Diverter in treating unruptured large and giant wide-neck intracranial aneurysms.

The flow diverter has been designed as a small cobalt chromium braided stent for directing blood flow inside an intracranial artery, away from a weakened blood vessel sac or aneurysm.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This blood flow diversion is meant to occlude the aneurysm over time, thereby decreasing the risk of rupture in the future.

“Stryker’s flow-diverting stent is said to be equipped to address aneurysms in the neck region by reliably opening and delivering consistent mesh density for the occlusion and maintenance of perforator artery patency.”

Surpass Streamline, which is already marketed in other international countries, is the second such device to obtain the US regulatory approval.

Stryker Neurovascular division president Mark Paul said: “The PMA approval of Surpass Streamline Flow Diverter in the US is an important milestone for the division.

“It expands our commercial footprint into the flow diversion market and reinforces our commitment to complete stroke care for patients suffering from cerebrovascular disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The treatment of unruptured aneurysms is considered more challenging due to their location and surrounding anatomy.

Stryker’s flow-diverting stent is said to be equipped to address these aneurysms in the neck region by reliably opening and delivering consistent mesh density for the occlusion and maintenance of perforator artery patency.

The FDA approval is based on clinical outcomes obtained during the prospective, multi-centre SCENT investigational device exemption (IDE) clinical trial.

According to the results, the trial met both primary and secondary endpoints, as well as demonstrated single stent efficacy with the Surpass Streamline Flow Diverter.

SCENT IDE trial co-principal investigator Ricardo Hanel said: “The ability to resheath, reposition and recapture the device without losing distal wire position is a significant advantage for Surpass.”